Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
74 Cards in this Set
- Front
- Back
G6PDH
Reactant and product |
Reactant: Glucose-6-P
Product: 6-phosphogluconate |
|
G6PDH
cofactor |
NADP
(rxn: NADP ---> NADPH) |
|
G6PDH
part of what pathway? |
Hexose monophosphate shunt
|
|
G6PDH
induced by |
insulin
|
|
G6PDH
activated by |
NADP (decrease in NADPH/NADP ratio)
|
|
G6PDH deficiency
inheritence |
XLR
|
|
G6PDH
major function |
Generate NADPH for anabolic purposes (EG: FA synthesis), antimicrobial killing and protection of cells from reactive oxygen species
|
|
Describe the role of NADPH in protecting against ROS (particularly in RBCs)
|
NADPH reduces oxidized Glutathionine (G-S-S-G) back to its reduced form (2 GSH). GSH allows the enzyme Glutathionine peroxidase to breakdown H202
|
|
G6PDH deficiency
3 key features |
-immunodeficiency (in severe disease)
- Heinz bodies -hemolytic anemia |
|
G6PDH deficiency
stressors that can acute hemolytic anemia |
-ifn
-drugs (sulfas, chloroquine) -fava beans |
|
G6PDH deficiency
Why can this condition lead to immunodeficiency? |
NAPDH oxidase generates bactericidal superoxide. NADPH deficiency inhibits this function.
|
|
CGD/NADPH deficiency
How can the diagnosis be confirmed |
a NEGATIVE nitroblue tetrazolium test
|
|
HMG CoA reductase
location |
ER
|
|
HMG CoA reductase
activated by? |
insulin
|
|
HMG CoA reductase
enzyme ACTIVITY is inhibited by |
-glucagon
-statins |
|
HMG CoA reductase
reaction |
HMG-CoA is converted to mevalonate
|
|
HMG CoA reductase
cholesterol effect on the enzyme |
Increased hepatic cholesterol represses expression and enhances degradation
|
|
HMG CoA reductase
How does inhibition by statin drugs decrease cholesterol levels? |
Inhibition by statins both decreases de novo synthesis and enhances hepatic clearence of serum cholesterol by increased LDLR expression
|
|
HMG CoA reductase
statins are _________ inhibitors |
competitive
|
|
DHFR
reaction it catalyzes |
Folate---->DHF--->THF
|
|
DHFR
eukaryotic inhibitior |
methotrexate
|
|
DHFR
prokaryotic inhibitors (2) |
-Trimethoprim
-pyrimethamine |
|
DHFR
Most important downstream consequence of inhibition? |
A block of DHFR function ultimately prevent synthesis of thymidylate (thymidylate synthase is folate dependent)
|
|
how can ornithine transcarbamylase deficiency be distinguished from orotic aciduria
|
OTCD has hyperammonia and low BUN
Orotic aciduria has a normal BUN |
|
Orotic Aciduria
enzymatic causes |
- orotic acid phosphoribosyltransferase deficiency
OR - OMP decarboxylase deficiency |
|
UDP-Glucuronyl transferase
key reaction |
Bilirubin + glucoronide ----> bilirubin-diglucoronide
|
|
UDP-Glucuronyl transferase
significance in neonates |
UDP-Glucuronyl transferase is the last enzyme expressed in infants. Thus, neonates have increased susceptibility to jaundice and kernicterus
|
|
Dubin-Johnson syndrome
characterized by |
black pigment in the liver due to impaired excretion of direct bilirubin
|
|
Crigler-Najjar syndrome
define |
a severe UDP-Glucuronyl transferase deficiency
|
|
Gilbert Syndrome
define |
a benign UDP-Glucuronyl transferase deficiency
|
|
gamma-glutamyl carboxylase
rxn: |
glu -----> gamma gultamic acid
|
|
gamma-glutamyl carboxylase
function and substrate of this rxn: |
gamma carboxylation of factors II, VII, IX, X and Protein C&S generates Ca binding sites.
|
|
gamma-glutamyl carboxylase
dependent on? |
vit K
|
|
gamma-glutamyl carboxylase
inhibited by |
warfarin and dicoumarol
|
|
Warfarin
does this drug inhibit in vitro clotting? |
NO, warfarin's effect (vit K reductase inhibition) prvents in vivo clotting by blocking clotting factor synthesis but has no effect on existant factors.
|
|
gamma-glutamyl carboxylase
this reaction catalyzes what type of modification |
cotranslational modification of clotting factors
|
|
Homocysteine methyltranferase
rxn: |
homocysteine ---> methionine
|
|
Homocysteine methyltranferase
cofactors: |
-N5-methyl THF
-methylcobalamin (B12) |
|
mild homocysteinuria is associated with deficiencies is what vitamins
|
folate
B12 B6 (cystathionine synthase rxn) |
|
mild homocysteinuria
symptoms |
-DVT
-stroke -atherosclerosis |
|
how can B12 deficiency be distinguished from folate deficiency?
|
B12 deficiency is associated with methylmalonic aciduria
|
|
name the 3 "ABC" carboxylases
|
(ATP, Biotin, Co2)
-propionyl-CoA carboxylase -acetyl-CoA carboxylase -pyruvate carboxylase |
|
Methylmalonyl-CoA mutase
rxn: |
Methylmalonyl-CoA ---> succinyl-CoA
|
|
Methylmalonyl-CoA mutase
cofactor: |
adeonsylcobalamin (B12)
|
|
Methylmalonyl-CoA mutase
deficiency results in: |
Methylmalonylic aciduria and peripheral neuropathy
|
|
Lesch-Nyhan Syndrome
inheritence: |
XLR
|
|
Lesch-Nyhan Syndrome
genetic cause: |
HGPRT deficiency
|
|
Lesch-Nyhan Syndrome
symptoms: |
-spastic cerebral palsy
-self-mutilation -hyperuricemia -early death |
|
6-Mercaptopurine is activated by
|
HGPRT
|
|
Lesch-Nyhan Syndrome
pathophysiology |
Loss of the salvage pathways results in shunting of Hypoxanthine and guanine to the excretion pathway.
Furthermore, loss of feedback inhibition of PRPP admidotransferase results in additional purine synthesis. Thus, HGPRT deficiency leads to crippling excesses of urate |
|
HGRPT
rxn: |
hypoxanthine/guanine -----> IMP/GMP
|
|
Branched-chain Ketoacid DH
cofactors: |
TPP
Lipoic acid CoA FAD NAD |
|
Branched-chain Ketoacid DH
critical in the metabolism of |
Valine
Leucine Isoleucine |
|
Branched-chain Ketoacid DH
associated disease: |
maple serup urine disease
|
|
maple serup urine disease
symptoms: |
-urine has a maple odor
-mental retardation -abnormal muscle tone -ketosis -coma,death |
|
name the substances that enter the propionyl-CoA pathway
|
(VOMIT)
Valine Odd chain FA Methionine Isoleucine Threonine |
|
Pyruvate DH
cofactors |
TPP
Lipoic Acid CoA FAD NAD |
|
Pyruvate DH
rxn: |
pyruvate------> acetyl CoA
|
|
Pyruvate DH
deficient in what population (consequence) |
alcoholics due to thiamine deficiency (results in lactic acidosis)
|
|
Pyruvate DH
inhibited by |
acetyl-CoA
|
|
PKU
genetic causes |
phenylalanine hyxdroxylase deficiency
OR tetrahydrobiopterin deficiency |
|
Aspartame is contraindicated in what condition
|
PKU
|
|
PKU
untreated symptoms |
-pale skin and white hair
-mental retardation -loss of motor control -musty, mousy odor |
|
PKU
-pathophysiology |
elevated phenylalanine has a neurotoxic effect
|
|
Phenylalanine hydroxylase
rxn |
phe ---> tyrosine
|
|
MCAD
function |
oxidation of medium chain FA
|
|
MCAD deficiency
symptoms |
-fasting hypoglycemia
- NO KETONES -C8-10 acyl carnitines in blood -DICARBOXYLIC ACIDEMIA |
|
Dicarboxylic acidemia is pathognomonic for
|
MCAD deficiency
|
|
Topoisomerase II
inhibited by what drug class in prokaryotes |
-quinolones
|
|
Topoisomerase II
function |
relieves positive supercoiling during DNA replication by introducing negative supercoils
|
|
Topoisomerase II
target for what drugs in eukaryotes |
etoposide
teniposide |
|
Excision endonuclease
function |
removal of intrastrand thymine dimers
|
|
Xerderma pigmentosum
defective gene |
excision endonuclease
|
|
Xerderma pigmentosum
symptoms |
extreme UV sensitivity
excessive freckling multiple skin cancers corneal ulcerations |